Aztreonam lysine | CAS#827611-49-4 | antibiotic

MedKoo Cat#: 597503 | Name: Aztreonam lysine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Aztreonam lysine is an inhaled anti-pseudomonal therapy for people with cystic fibrosis (CF) who have pulmonary Pseudomonas aeruginosa infection.

Chemical Structure

Aztreonam lysine

CAS#827611-49-4

Theoretical Analysis

MedKoo Cat#: 597503

Name: Aztreonam lysine

CAS#: 827611-49-4

Chemical Formula: C19H31N7O10S2

Exact Mass:

Molecular Weight: 581.61

Elemental Analysis: C, 39.24; H, 5.37; N, 16.86; O, 27.51; S, 11.02

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Aztreonam lysine; Corus 1020; Aztreonam lysinate; Corus1020; Corus-1020;

IUPAC/Chemical Name

L-lysine compound with 2-((((Z)-1-(2-aminothiazol-4-yl)-2-(((2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid (1:1)

InChi Key

KPPBAEVZLDHCOK-JHBYREIPSA-N

InChi Code

InChI=1S/C13H17N5O8S2.C6H14N2O2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22;7-4-2-1-3-5(8)6(9)10/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25);5H,1-4,7-8H2,(H,9,10)/b17-8-;/t5-,7-;5-/m00/s1

SMILES Code

N[C@@H](CCCCN)C(O)=O.CC(C)(O/N=C(C1=CSC(N)=N1)\C(N[C@H]2[C@H](C)N(S(=O)(O)=O)C2=O)=O)C(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 581.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Schechter MS, Trueman D, Farquharson R, Higuchi K, Daines CL. Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation. Ann Am Thorac Soc. 2015 Jul;12(7):1030-8. doi: 10.1513/AnnalsATS.201312-453OC. PubMed PMID: 26053185. 2: Hutchinson D, Barclay M, Prescott WA, Brown J. Inhaled aztreonam lysine: an evidence-based review. Expert Opin Pharmacother. 2013 Oct;14(15):2115-24. doi: 10.1517/14656566.2013.831070. Epub 2013 Aug 31. Review. PubMed PMID: 23992352. 3: Assael BM, Pressler T, Bilton D, Fayon M, Fischer R, Chiron R, LaRosa M, Knoop C, McElvaney N, Lewis SA, Bresnik M, Montgomery AB, Oermann CM; AZLI Active Comparator Study Group. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros. 2013 Mar;12(2):130-40. doi: 10.1016/j.jcf.2012.07.006. Epub 2012 Sep 15. PubMed PMID: 22985692. 4: Zeitler K, Salvas B, Stevens V, Brown J. Aztreonam lysine for inhalation: new formulation of an old antibiotic. Am J Health Syst Pharm. 2012 Jan 15;69(2):107-15. doi: 10.2146/ajhp100624. Review. PubMed PMID: 22215356. 5: Pesaturo KA, Horton ER, Belliveau P. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1076-85. doi: 10.1345/aph.1Q653. Epub 2012 Jul 3. Review. PubMed PMID: 22764322. 6: Guglani L, Abdulhamid I, Ditouras J, Montejo J. Desensitization to inhaled aztreonam lysine in an allergic patient with cystic fibrosis using a novel approach. Ann Pharmacother. 2012 Oct;46(10):e25. doi: 10.1345/aph.1R293. Epub 2012 Sep 25. PubMed PMID: 23012384. 7: Parkins MD, Elborn JS. Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis. Expert Rev Respir Med. 2010 Aug;4(4):435-44. doi: 10.1586/ers.10.48. Review. PubMed PMID: 20658904. 8: Plosker GL. Aztreonam lysine for inhalation solution in cystic fibrosis: profile report. Paediatr Drugs. 2011 Apr 1;13(2):129-31. doi: 10.2165/11206940-000000000-00000. PubMed PMID: 21351813. 9: Plosker GL. Aztreonam lysine for inhalation solution: in cystic fibrosis. Drugs. 2010 Oct 1;70(14):1843-55. doi: 10.2165/10484070-000000000-00000. Review. PubMed PMID: 20836577. 10: O'Sullivan BP, Yasothan U, Kirkpatrick P. Inhaled aztreonam. Nat Rev Drug Discov. 2010 May;9(5):357-8. doi: 10.1038/nrd3170. PubMed PMID: 20431562. 11: Whitaker P, Etherington C, Williams K, Conway S, Peckham D. The use of nebulised aztreonam lysine (AZLI) in aztreonam hypersensitive patients. J Cyst Fibros. 2012 Jul;11(4):353. doi: 10.1016/j.jcf.2012.01.007. Epub 2012 Feb 16. PubMed PMID: 22341263. 12: Iglesias A, Artiles I, Cabanillas JJ, Alvarez-Sala R, Prados C. Eradication of Burkholderia cepacia Using Inhaled Aztreonam Lysine in Two Patients with Bronchiectasis. Case Rep Pulmonol. 2014;2014:192146. doi: 10.1155/2014/192146. Epub 2014 Sep 9. PubMed PMID: 25295210; PubMed Central PMCID: PMC4175385. 13: Hansen C, Skov M. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis. Ther Adv Respir Dis. 2015 Feb;9(1):16-21. Review. PubMed PMID: 25471692. 14: Sole A, Poveda JL, Giron RM, Prados MC, De GJ, Casado MÁ. Economic Impact Linked To the Reduction of Exacerbations When A Treatment Regime With Inhaled Antibiotics Is Switched To Aztreonam Lysine In Patients With Cystic Fibrosis and Chronic Pulmonary Infection Caused By Pseudomonas Aeruginosa. Value Health. 2014 Nov;17(7):A526. doi: 10.1016/j.jval.2014.08.1659. Epub 2014 Oct 26. PubMed PMID: 27201659. 15: Tiddens HA, De Boeck K, Clancy JP, Fayon M, H G M A, Bresnik M, Derchak A, Lewis SA, Oermann CM; ALPINE study investigators. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study. J Cyst Fibros. 2015 Jan;14(1):111-9. doi: 10.1016/j.jcf.2014.06.003. Epub 2014 Aug 1. PubMed PMID: 25091537. 16: Elborn JS, Henig NR. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine. Expert Opin Pharmacother. 2010 Jun;11(8):1373-85. doi: 10.1517/14656566.2010.482102. Review. PubMed PMID: 20426707. 17: Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, Cooper PJ. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol. 2010 Nov;45(11):1121-34. doi: 10.1002/ppul.21301. PubMed PMID: 20672296; PubMed Central PMCID: PMC3867945. 18: Nick JA, Moskowitz SM, Chmiel JF, Forssén AV, Kim SH, Saavedra MT, Saiman L, Taylor-Cousar JL, Nichols DP. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc. 2014 Mar;11(3):342-50. doi: 10.1513/AnnalsATS.201310-352OC. PubMed PMID: 24476418; PubMed Central PMCID: PMC4028742. 19: Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009 May;135(5):1223-1232. doi: 10.1378/chest.08-1421. PubMed PMID: 19420195; PubMed Central PMCID: PMC2818415. 20: McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008 Nov 1;178(9):921-8. doi: 10.1164/rccm.200712-1804OC. Epub 2008 Jul 24. PubMed PMID: 18658109; PubMed Central PMCID: PMC2577727.